Shots:sstosohShots:

• The P-II ORIENT-2 study involves assessing TYVYT as monothx. vs paclitaxel/ rinotecan in 190 patients in a ratio (1:1) with advanced or metastatic ESCC who failed 1L treatment
• The P-II ORIENT-2 resulted in meeting its 1EPs of OS with no news safety signals. The detailed results will be presented at ASCO 2020. The two companies plan to discuss results with NMPA’s CDE in China
•  TYVYT is a type of IgG4 mAb that binds to PD-1 on the surface of T-cells acts by blocking the PD-1/ PD-L1 pathway and reactivates T-cells to kill cancer cells. The NMPA has accepted sNDA for TYVYT + ALIMTA (pemetrexed) and platinum as 1L in NSCLC in Apr’2020 while the therapy in combination with Gemzar (gemcitabine) and platinum CT in P-III ORIENT-12 study as 1L therapy with LA/metastatic sq.NSCLC

Click here ­to­ read full press release/ article 

Ref: PRNewswire  | Image: Innovent